JP2009527484A5 - - Google Patents

Download PDF

Info

Publication number
JP2009527484A5
JP2009527484A5 JP2008555417A JP2008555417A JP2009527484A5 JP 2009527484 A5 JP2009527484 A5 JP 2009527484A5 JP 2008555417 A JP2008555417 A JP 2008555417A JP 2008555417 A JP2008555417 A JP 2008555417A JP 2009527484 A5 JP2009527484 A5 JP 2009527484A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
zileuton
composition according
single crystal
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008555417A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009527484A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/004488 external-priority patent/WO2007098189A2/en
Publication of JP2009527484A publication Critical patent/JP2009527484A/ja
Publication of JP2009527484A5 publication Critical patent/JP2009527484A5/ja
Pending legal-status Critical Current

Links

JP2008555417A 2006-02-21 2007-02-21 (+)−r−ジロートンの新規結晶形態および医薬組成物 Pending JP2009527484A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77557906P 2006-02-21 2006-02-21
PCT/US2007/004488 WO2007098189A2 (en) 2006-02-21 2007-02-21 New crystal forms and pharmaceutical compositions of (+) -r-zileuton

Publications (2)

Publication Number Publication Date
JP2009527484A JP2009527484A (ja) 2009-07-30
JP2009527484A5 true JP2009527484A5 (cg-RX-API-DMAC7.html) 2010-04-08

Family

ID=38437967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008555417A Pending JP2009527484A (ja) 2006-02-21 2007-02-21 (+)−r−ジロートンの新規結晶形態および医薬組成物

Country Status (6)

Country Link
US (1) US8003684B2 (cg-RX-API-DMAC7.html)
EP (2) EP2001861A2 (cg-RX-API-DMAC7.html)
JP (1) JP2009527484A (cg-RX-API-DMAC7.html)
AU (1) AU2007217770B2 (cg-RX-API-DMAC7.html)
CA (1) CA2642216A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007098189A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
CA2674492A1 (en) * 2007-01-05 2008-07-17 Cornerstone Therapeutics Inc. Method for the treatment of conditions associated with increased 5-lipoxygenase and/or leukotriene activity
WO2009045291A2 (en) * 2007-09-28 2009-04-09 The Brigham And Women's Hospital, Inc. Mast cell stabilizers in the treatment of obesity
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
EP2747762B1 (en) * 2011-08-23 2015-07-01 Cornerstone Therapeutics Inc. Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients
US9855243B2 (en) 2013-10-30 2018-01-02 Qurient Co., Ltd. Topical anti-inflammatory pharmaceutical composition with zileuton cream formulation
KR101462474B1 (ko) * 2013-10-30 2014-11-19 주식회사 큐리언트 질레우톤 크림 제형의 국소용 항염증 약학적 조성물
KR20170012332A (ko) * 2014-06-20 2017-02-02 아비라겐 테라퓨틱스, 인코포레이티드 [2-[1-(6-메틸-3-피리다지닐)-4-피페리디닐]에톡시]-3-에톡시-1,2-벤즈이속사졸의 무수 결정성 유리 염기 형태

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US279263A (en) * 1883-06-12 Eobeet t
ES2059408T3 (es) * 1987-02-10 1994-11-16 Abbott Lab Un proceso para la preparacion de un compuesto.
EP0697868A4 (en) * 1993-05-10 1998-04-08 Sepracor Inc THERAPIES AND COMPOSITIONS USING OPTICALLY PURE (+) - ZILEUTON
JPH09500139A (ja) 1993-07-14 1997-01-07 スミスクライン・ビーチャム・コーポレイション ヒドロキシルアミンの酸付加塩の合成法

Similar Documents

Publication Publication Date Title
US20230373955A1 (en) Synthesis of omecamtiv mecarbil
US10035802B2 (en) Solid state forms of ibrutinib
JP2013529647A5 (cg-RX-API-DMAC7.html)
JP2014515372A5 (cg-RX-API-DMAC7.html)
JP2019505568A5 (cg-RX-API-DMAC7.html)
WO2014152270A1 (en) Salt of omecamtiv mecarbil and process for preparing salt
JP2007514746A5 (cg-RX-API-DMAC7.html)
JP2011513485A5 (cg-RX-API-DMAC7.html)
JP6556293B2 (ja) 純粋なニロチニブ及びその塩の調製のための方法
KR20190133726A (ko) 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1H-1,2,4-트리아졸-3-일)페닐)아미노)-N-(메틸-d3)피리다진-3-카르복스아미드의 결정 형태
US10519117B2 (en) Crystal forms of 6-bromo-3-hydroxy-2-pyrazinecarboxamide
WO2016107289A1 (zh) 制备索非布韦晶型6的方法
CN104628679A (zh) Bitopertin的新合成方法及其中间体
WO2024114106A1 (zh) 一种甲磺草胺中间体的合成方法
JP2013541589A5 (cg-RX-API-DMAC7.html)
JP2009541438A5 (cg-RX-API-DMAC7.html)
CN103951601B (zh) 2-乙酰基-1-吡咯啉的合成方法
CN105777617A (zh) 色瑞替尼的合成中间体及其制备方法
US10774042B2 (en) Crystalline forms of apremilast
JP2018024683A (ja) 逆転写酵素阻害剤の結晶形態
WO2012153225A1 (en) Improved processes for obtaining high purity of dronedarone hydrochloride
CN101896496B (zh) 4-脱氧-4-氟-d-葡萄糖衍生物的制造方法
EP3374349A1 (en) Process for the preparation of eltrombopag olamine
JPWO2005058914A1 (ja) オキサセフェムの結晶
CN114364380A (zh) (s)-2-((2s,3r)-1-氨基-3-羟基-1-氧代丁烷-2-基)-1-氧代-2,5-二氮杂螺[3.4]辛烷-5-甲酸叔丁酯的固体形式及其制备方法